3-azabicyclo[3.1.0]hexane-6-carboxylic acid | 1212105-25-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-azabicyclo[3.1.0]hexane-6-carboxylic acid
• 英文别名: (1α,5α,6β)-3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid
• CAS: 1212105-25-3
• 化学式: C₆H₉NO₂
• 分子量: 127.14
• InChiKey: QWFCVBMSMZUVFU-ZXFHETKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.46
• 重原子数：
  9.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.33
• 氢给体数：
  2.0
• 氢受体数：
  2.0

文献信息

• PHARMACEUTICAL COMPOUNDS
  申请人：Heptares Therapeutics Limited

  公开号：US20180362507A1

  公开（公告）日：2018-12-20

  This invention relates to compounds that are agonists of the muscarinic M 1 and/or M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X 1 ; X 2 ; R 1 and R 4 are as defined herein.

  这项发明涉及激动毒蕈碱M1和/或M4受体的化合物，这些化合物在治疗由毒蕈碱M1和M4受体介导的疾病中有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物的化学式如下： 其中X1；X2；R1和R4如本文所定义。
• RHO KINASE INHIBITORS
  申请人：Bosanac Todd

  公开号：US20080161297A1

  公开（公告）日：2008-07-03

  Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

  揭示了一种新颖的取代的2H-异喹啉-1-酮和3H-喹唑啉-4-酮衍生物，可用作Rho激酶的抑制剂，用于治疗通过Rho激酶活性介导或维持的各种疾病和疾病，包括心血管疾病，包含这些化合物的药物组合物，使用这些化合物的方法以及制备这些化合物的方法。
• 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES
  申请人：Caroff Eva

  公开号：US20120028989A1

  公开（公告）日：2012-02-02

  The present invention relates to 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidine derivatives and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-苯基-嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的病症，包括在人类和其他哺乳动物中的血栓形成的使用。
• sGC STIMULATORS
  申请人：IRONWOOD PHARMACEUTICALS, INC.

  公开号：US20160031903A1

  公开（公告）日：2016-02-04

  Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

  本文描述了化学式I'和I的化合物，它们可用作sGC的刺激剂，特别是NO独立，血红素依赖性的刺激剂。这些化合物还可用于治疗、预防或管理本文中披露的各种疾病。
• [EN] CARBOXYLIC ACID CONTAINING INDANYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS INDANYLES CONTENANT DE L'ACIDE CARBOXYLIQUE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：CELGENE CORP

  公开号：WO2022140555A1

  公开（公告）日：2022-06-30

  Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.

  本文提供了用于调节S1P5的化合物及其组合物。在某些实施例中，这些化合物和组合物被用于治疗神经系统疾病。